RATIONALE: Chlorhexidine is an antimicrobial agent used in the dialysis setting for disinfection of skin and fistula/catheter exit sites. Allergic reactions to chlorhexidine have been reported; recently, there have been several case reports of anaphylaxis from chlorhexidine-impregnated central lines in dialysis patients undergoing renal transplantation. Dialysis patients and healthcare workers may be at risk for chlorhexidine sensitization. METHODS: Nurses and patients were recruited from hemodialysis units at the Toronto General Hospital and administered a questionnaire regarding allergic symptoms to chlorhexidine and/or a chlorhexidine skin prick test (SPT). Specific IgE (sIgE) to chlorhexidine was measured from plasma samples of participants with allergy-suggestive symptoms or SPTs. Independent samples t-test and Fisher's exact test were used for analyses. RESULTS: We recruited 63 participants (29 nurses and 34 patients). Compared to patients, nurses had longer (146 vs 84 months, p<0.05) and more frequent chlorhexidine exposures (62% vs 12% reporting > _4 exposures/week, p<0.001). Most nurses (76%) reported regular direct skin exposure to chlorhexidine. Pruritus associated with chlorhexidine and absent with other cleaning agents was reported by 41% of patients and 14% of nurses (p<0.05). Positive SPT responses were observed in 10% of patients and 9% of nurses. One nurse and 2 patients had both chlorhexidine-associated pruritus and a positive SPT. Users of chlorhexidine foam (n52) and wipes (n51) recalled associated severe pruritus and/or a rash. CONCLUSIONS: We found a 6% generalized prevalence (3% of nurses and 9% of patients) of chlorhexidine allergy in a hemodialysis setting. Our study will continue by assessing associations of findings with sIgE measurements.
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Nasal IL-15 levels are similar between asthmatics and controls during asthma exacerbations and viral upper respiratory infections RATIONALE: Eighty percent of children with asthma exacerbations will have an associated viral infection. Asthmatics with low IL-15 levels have been shown to have higher symptoms during experimental rhinovirus challenge. We evaluated nasal filter paper from children during asthma exacerbations and compared them to the acute symptoms experienced by the children to find correlations. Further, we correlated IL-15 levels with acute symptoms in the asthma group. METHODS: We recruited 83 patients (exacerbating asthma, n 5 58; controls, n5 25) ages 4-18 years with upper respiratory infection symptoms from the Emergency Department. Baseline Pediatric Respiratory Symptoms (PRS) Scores were recorded. Nasopharyngeal swabs were used to detect the presence of respiratory viruses by viral genome sequencing. Nasal filter paper was used to collect nasal mucosal lining fluid, and, after elution, inflammatory mediators were analyzed using bead-array immunoassays. RESULTS: IL-15 levels were found to be higher in all patients with viral infections than those without (Median5 5.50pg/mL and 2.88pg/mL, respectively; p<0.05). IL-15 levels were similar between subjects with viral-induced asthma exacerbations and controls with viral-induced cold symptoms (p5NS). In the asthma subjects, there was some positive correlation between IL-15 levels and acute symptoms by PRS (R 2 50.08, p<0.05). CONCLUSIONS: Despite previous reports of IL-15 deficiency in asthmatics, we confirm similar IL-15 responses in exacerbating asthmatics and controls. Furthermore, in a cross-sectional study, we found that asthmatics with higher IL-15 levels have more acute respiratory symptoms.
Development of Attenuated and Immunogenic Live-attenuated Respiratory Syncytial Virus Vaccine Candidates
Sandra L. Hornung, Kim C. Tran, and Michael N. Teng, PhD; University of South Florida, Tampa, FL. RATIONALE: Despite decades of research, properly attenuated and immunogenic live-attenuated vaccines for respiratory syncytial virus (RSV) have remained elusive. Our goal in this study was to identify recombinant RSV bearing mutations in the NS1 gene that allow for increased production of IFN from infected cells and that are properly attenuated in animal models. METHODS: NS1 expression plasmids containing C-terminal deletion mutations were tested for IFN antagonism using a luciferase-based reporter assay. NS1 deletion mutants found to have diminished IFN antagonism by IFN reporter assay were inserted into recombinant RSV and assayed for IFN induction by qRT-PCR and bioassay and for multiple step replication in A549 and Vero cells. RESULTS: Our previous studies identified regions in the N-terminus of NS1 that are important for IFN antagonism and viral replication. We have now extended these findings to the C-terminal region of NS1. We find that the C-terminal 20 aa of NS1 include specific residues important for either IFN antagonism or viral replication. In addition, we find that viruses that display decreased IFN antagonism are as attenuated as NS1-deletion RSV in IFN-sufficient A549 cells but are only moderately attenuated in IFNdeficient Vero cells. CONCLUSIONS: Our results add to our menu of NS1 mutations that can be used to fine-tune IFN production and viral replication, thus allowing for greater control over the immunogenicity and attenuation of recombinant RSV.
